Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium bromide

Study type: Observational

Funder types: Industry

Identifiers

NCT02172521

205.320

Details and patient eligibility

About

• Primary objective of this observational study was to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (COPD) and demonstrated hyperinflation.
• Secondary objective was to obtain safety data regarding adverse events.

Enrollment: 1,536 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women and men with diagnosis of chronic obstructive pulmonary disease (COPD) with a thoracic gas volume (TGV) > = 120% as measured by body plethysmography
• Only patients who have not yet been treated with Spiriva® 18 micrograms can be included in the study.

Exclusion criteria

• Patients who presenting the general and specific contraindications mentioned in the Patient Information and Prescribing Information

Trial design

1,536 participants in 1 patient group

COPD and proven hyperinflation

Description:

Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram

Treatment:

Drug: Tiotropium bromide